Read More Pharma Industry News Symic Bio initiates SB-030 Phase 1/2a study in peripheral artery disease Symic Bio, a biopharmaceutical company based in California specializing in matrix biology, is set to commence a phase… bypharmanewsdailyFebruary 25, 2017